autologous HIV Gag-specific CD4+ T cells AGT103-T

A preparation of autologous, human immunodeficiency virus (HIV) Gag-specific, cluster of differentiation 4 (CD4)-positive T lymphocytes, with potential antiviral activity. Autologous HIV Gag-specific CD4+ T cells AGT103-T are prepared via ex vivo stimulation of autologous peripheral blood mononuclear cells (PBMCs) with Gag peptides, and the Gag-specific CD4+ T cells are transduced with the recombinant lentiviral vector AGT103 encoding inhibitory RNA targeting the HIV coreceptor C-C chemokine receptor type 5 (CCR5) and HIV sequences within the Vif/Tat coding regions. Upon administration, autologous HIV Gag-specific CD4+ T cells AGT103-T may prevent infection by CCR5- or CXCR4-tropic strains of HIV, reduce the depletion of CD4+ T cells upon HIV exposure and prevent latently-infected cells from releasing new HIV particles.